Skip to search formSkip to main contentSkip to account menu

Percus passerinii

Known as: Percus passerini 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
Background: Ponatinib is a potent oral tyrosine kinase inhibitor (TKI) approved for pts with CP-CML or Ph+ ALL for whom no other… 
2017
2017
Observational Study of CML Italian Patients Who Discontinued TKIs
Background: Different studies analysed the outcome of patients (pts) who discontinued tyrosine kinase inhibitors (TKIs) reporting… 
2017
2017
Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update
Bosutinib is an orally active, dual SRC/ABL tyrosine kinase inhibitor (TKI) approved for treating adult patients with chronic… 
2013
2013
High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients
![Graphic][1] In hematological disorders ALK expression is present in >50% of Anaplastic Large Cell Lymphomas (ALCL) as a… 
2012
2012
Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study
Abstract 69 Bosutinib (BOS) is an oral, dual Src/Abl kinase inhibitor. In the randomized, phase 3 BELA trial, BOS 500 mg/d… 
2012
2012
Why are patients with chronic myeloid leukaemia (non-)adherent?
Until the advent of imatinib as an alternative to interferon alfa, chronic myeloid leukaemia (CML) was a lethal disease with a… 
2012
2012
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update
Abstract 3779 Bosutinib (BOS) is an oral, dual Src/Abl kinase inhibitor with minimal inhibitory activity against PDGFR or c-KIT… 
2012
2012
Radiolarian Age Constraints of Mid-Cretaceous Black Shales in Northern Tunisia
Mid-Cretaceous pelagic deposits outcropping in Northern Tunisia include organic-rich beds locally associated with high abundance… 
2005
2005
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid… 
2000
2000
Dragons 'Round the Fleece Again: STI571 Versus α1 Acid Glycoprotein
Ovid recounts the story of Jason and his Argonauts (1), who, after dealing with jealous harpies, wandering rocks, spectral armies… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)